Strategies to Modulate the Blood-Brain Barrier for Directed Brain Tumor Targeting

Paula Schiapparelli, Montserrat Lara-Velazquez, Rawan Al-kharboosh, Hao Su, Honggang Cui, Alfredo Quinones-Hinojosa

Research output: Chapter in Book/Report/Conference proceedingChapter


Glioblastoma (GBM) is the most common and aggressive primary brain tumors in adults. Despite being one of the most genetically and molecularly characterized tumors, patient prognosis remains dismal. Many factors have contributed to the challenges of developing effective clinical therapies, such as tumor heterogeneity, immune-suppressive microenvironment, and therapy resistance. From the perspective of therapeutics delivery, one of the main obstacles is to get newly discovered therapeutic agents across the blood-brain barrier (BBB) to penetrate the brain parenchyma. In this context, this book chapter provides an overview of three different strategies of delivering antitumor agents intended to circumvent the BBB and highlight the strengths and weakness of each approach.

Original languageEnglish (US)
Title of host publicationNeuromethods
PublisherHumana Press Inc.
Number of pages30
StatePublished - 2021

Publication series

ISSN (Print)0893-2336
ISSN (Electronic)1940-6045


  • BBB permeability
  • Blood-brain barrier
  • Brain drug delivery
  • Convection-enhanced delivery (CED)
  • Focused ultrasound (FUS)
  • Glioma
  • Supramolecular hydrogels

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • General Pharmacology, Toxicology and Pharmaceutics
  • General Biochemistry, Genetics and Molecular Biology
  • General Neuroscience


Dive into the research topics of 'Strategies to Modulate the Blood-Brain Barrier for Directed Brain Tumor Targeting'. Together they form a unique fingerprint.

Cite this